access

News

Roche breast cancer drug Itovebi turned down by NICE

NICE turns down NHS use of Roche's breast cancer drug Itovebi, which the company says reveals a flaw in the appraisal of combination therapies.

News

Pharma leaders urge Europe to halt 'slow agony' of decline

Europe's top pharma firms have called on governments to take action to change the region's story from one of decay to one of "renewal and resilience."

News

UK first country to launch CSL's trivalent flu shot Aujemflu

CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.

News

Advocacy group pokes holes in Trump's MFN pricing claims

Public Citizen says claims for the drug price savings that are being delivered by Trump's Most-Favoured Nation deals with pharma are "a mirage."

News

MPs seek probe into UK-US pharma deal's impact on NHS

The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.

News

MFN affecting Swiss medicines access, says Interpharma

Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.

Roche breast cancer drug Itovebi turned down by NICE

Pharma leaders urge Europe to halt 'slow agony' of decline

UK first country to launch CSL's trivalent flu shot Aujemflu

Advocacy group pokes holes in Trump's MFN pricing claims

MPs seek probe into UK-US pharma deal's impact on NHS

MFN affecting Swiss medicines access, says Interpharma

Astellas pays $285m for Audax cancer drug, and other deals

Discover a new era of healthcare panel engagement: Grounded ...

access

Editor's Picks